Overview of lithium's use: a nationwide survey
dc.contributor.author | Pérez de Mendiola, Xabier | |
dc.contributor.author | Hidalgo Mazzei, Diego | |
dc.contributor.author | Vieta, Eduard | |
dc.contributor.author | González Pinto Arrillaga, Ana María | |
dc.date.accessioned | 2021-03-24T13:30:20Z | |
dc.date.available | 2021-03-24T13:30:20Z | |
dc.date.issued | 2021-03-09 | |
dc.identifier.citation | International journal of bipolar disorders 9 : (2021) // Article ID 10 | es_ES |
dc.identifier.issn | 2194-7511 | |
dc.identifier.uri | http://hdl.handle.net/10810/50762 | |
dc.description.abstract | BACKGROUND: Lithium is considered the gold standard treatment for bipolar disorder (BD). Current clinical guidelines and scientific evidence support its use as a first-line treatment in BD. However, over the last two decades, there has been a downward tendency in lithium's use in several developed countries. Based on a nationwide survey, this study's objective is to analyze in a large sample of psychiatrists relevant issues of the use of lithium salts in BD. METHODS: Data were collected through an anonymous survey sent by email among 500 psychiatrists who belong to a National Society of Psychiatry (Spanish Society of Biological Psychiatry). The survey is a self-administered questionnaire consisting of 21 items on the most key aspects of lithium's use (indication, dosage, monitoring, and information for patients). RESULTS: 212 psychiatrists completed the survey. 70% of psychiatrists prescribe lithium to more than 50% of patients diagnosed with BD. Adverse effects are the main reason not to use lithium salts. Over 75% of the participants consider lithium salts the treatment of choice for the maintenance phase of BD, both in women and men. Most of the participants (>50%) start lithium after the first affective episode, use conservative plasma concentrations (0.6-0.8mmol/L), and generally prescribe it twice a day. 57% of psychiatrists who treat patients under 18 do not use lithium in this population. About 70% of the survey respondents use official protocols to inform and monitor patients on lithium treatment. CONCLUSIONS: From the results of the present study, it can be concluded that the use of lithium in Spain is in line with the recommendations of the main international clinical guidelines and current scientific literature. The first reason not to prescribe lithium in our country is the perception of its adverse effects and not the aspects related to its practical use or its effectiveness. Considering that BD is a chronic disease with a typical onset in adolescence, the low rate of prescription of lithium salts in patients under 18 must be thoroughly studied. | es_ES |
dc.description.sponsorship | This work was supported by Carlos III Health Research Institute [Grant Number PI18/0155] (co-financed by the European Regional Development Fund (FEDER/ERDF)/European Social Fund 'Investing in your future'); Networking Center for Biomedical Research in Mental Health (CIBERSAM), the Basque Government [Grant number, 2017111104] and the University of the Basque Country [Grant Number 321212ELBY]. The psychiatric research department in Araba University Hospital is supported by the Stanley Research Foundation [Grant number 03-RC-003].. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | adolescence onset | es_ES |
dc.subject | adverse effects | es_ES |
dc.subject | bipolar disorders | es_ES |
dc.subject | dosing schedule | es_ES |
dc.subject | first episode | es_ES |
dc.subject | lithium | es_ES |
dc.subject | psychiatrists attitude | es_ES |
dc.subject | survey | es_ES |
dc.title | Overview of lithium's use: a nationwide survey | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-020-00215-z#rightslink | es_ES |
dc.identifier.doi | 10.1186/s40345-020-00215-z | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.